Microbot MedicalFRA:CY9D +4.89%32 EBITDA Margin % is -4,094.51% as of Mar. 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Microbot Medical ranks worse than 98.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Microbot Medical's EBITDA for the
three
months ended in Mar. 2026 was €-3.73 Mil. Microbot Medical's Revenue for the
three
months ended in Mar. 2026 was €0.09 Mil. Therefore, Microbot Medical's EBITDA margin for the quarter that ended in Mar. 2026 was -4,094.51%.
Microbot Medical (FRA:CY9D) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Microbot Medical EBITDA Margin % Related Terms
Microbot Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Microbot Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CY9D vs STXS, POCI, DXR: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Microbot Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Microbot Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical (FRA:CY9D) has a EBITDA Margin % of -4,094.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Microbot Medical and its competitors. According to the industry distribution chart, Microbot Medical ranks #807 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98.9%.
Is Microbot Medical's EBITDA Margin % too high?
Microbot Medical's current EBITDA Margin % is -4,094.51%. Based on the distribution chart, Microbot Medical ranks #807 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Microbot Medical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's EBITDA Margin % compare to STXS and POCI?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #807 out of 816 companies for EBITDA Margin %. This places Microbot Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.46, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Microbot Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Microbot Medical's current EBITDA Margin % is -4,094.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current EBITDA Margin % of -4,094.51%. The current EBITDA Margin % is -4,094.51%. Microbot Medical's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current EBITDA Margin % is -4,094.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
32GF Score
Get the complete analysis for FRA:CY9D
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CY9D has been successfully added to your 
